DK3580220T3 - Aminotriazolpyridiner som kinasehæmmere - Google Patents

Aminotriazolpyridiner som kinasehæmmere Download PDF

Info

Publication number
DK3580220T3
DK3580220T3 DK18707498.4T DK18707498T DK3580220T3 DK 3580220 T3 DK3580220 T3 DK 3580220T3 DK 18707498 T DK18707498 T DK 18707498T DK 3580220 T3 DK3580220 T3 DK 3580220T3
Authority
DK
Denmark
Prior art keywords
aminotriazolpyridines
inhibitors
chinese
chinese inhibitors
Prior art date
Application number
DK18707498.4T
Other languages
English (en)
Inventor
Junqing Guo
Amy C Hart
John E Macor
Michael E Mertzman
William J Pitts
Steven H Spergel
Scott Hunter Watterson
Murugaiah Subbaiah Murugaiah Andappan
Jie Chen
Carolyn Diane Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3580220T3 publication Critical patent/DK3580220T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
DK18707498.4T 2017-02-13 2018-02-12 Aminotriazolpyridiner som kinasehæmmere DK3580220T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
DK3580220T3 true DK3580220T3 (da) 2022-01-10

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18707498.4T DK3580220T3 (da) 2017-02-13 2018-02-12 Aminotriazolpyridiner som kinasehæmmere

Country Status (24)

Country Link
US (2) US10913738B2 (da)
EP (1) EP3580220B1 (da)
JP (1) JP7097373B2 (da)
KR (1) KR102549952B1 (da)
CN (1) CN110520423B (da)
AU (1) AU2018217488B2 (da)
BR (1) BR112019016635A2 (da)
CA (1) CA3053484A1 (da)
CY (1) CY1124978T1 (da)
DK (1) DK3580220T3 (da)
EA (1) EA039808B1 (da)
ES (1) ES2902676T3 (da)
HR (1) HRP20212000T1 (da)
HU (1) HUE057801T2 (da)
IL (1) IL268614B (da)
LT (1) LT3580220T (da)
MA (1) MA47460A (da)
MX (1) MX2019009555A (da)
PL (1) PL3580220T3 (da)
PT (1) PT3580220T (da)
RS (1) RS62801B1 (da)
SG (1) SG11201907335UA (da)
SI (1) SI3580220T1 (da)
WO (1) WO2018148626A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3580220T1 (sl) * 2017-02-13 2022-01-31 Bristol-Myers Squibb Company Aminotriazolopiridini kot kinazni inhibitorji
SI3704118T1 (sl) * 2017-10-30 2022-04-29 Bristol-Myers Squibb Company Aminoimidazopiridazini kot kinazni inhibitorji
EP3743430B1 (en) 2018-01-26 2023-08-02 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
US20210139456A1 (en) * 2018-07-09 2021-05-13 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
KR20210060516A (ko) 2018-09-13 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
CA3127701C (en) * 2019-01-25 2023-08-15 Beijing Scitech-Mq Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
CN113508109B (zh) * 2019-03-22 2023-02-10 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物,其制法与医药上的用途
EP4105216A4 (en) * 2020-02-13 2024-02-28 Genfleet Therapeutics Shanghai Inc DIHYDRONAPHTHYRIDINONE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL USE THEREOF
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
CN117460722A (zh) 2021-08-10 2024-01-26 艾伯维公司 烟酰胺ripk1抑制剂
CN116574053A (zh) * 2022-06-21 2023-08-11 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288502A1 (en) 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
BR112015030774A2 (pt) 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
EP3182974A1 (en) * 2014-08-21 2017-06-28 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
BR112018008765B1 (pt) 2015-11-05 2022-05-24 Sumitomo Chemical Company, Limited Composto heterocíclico condensado, composição e método para o controle de um artrópode nocivo
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
SI3580220T1 (sl) * 2017-02-13 2022-01-31 Bristol-Myers Squibb Company Aminotriazolopiridini kot kinazni inhibitorji
SI3704118T1 (sl) 2017-10-30 2022-04-29 Bristol-Myers Squibb Company Aminoimidazopiridazini kot kinazni inhibitorji
EP3743430B1 (en) 2018-01-26 2023-08-02 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
JP7097373B2 (ja) 2022-07-07
US20220315580A1 (en) 2022-10-06
US20190389859A1 (en) 2019-12-26
KR20190117006A (ko) 2019-10-15
PL3580220T3 (pl) 2022-02-07
SG11201907335UA (en) 2019-09-27
MA47460A (fr) 2019-12-18
CN110520423A (zh) 2019-11-29
SI3580220T1 (sl) 2022-01-31
IL268614B (en) 2021-12-01
US10913738B2 (en) 2021-02-09
AU2018217488B2 (en) 2021-09-23
IL268614A (en) 2019-10-31
WO2018148626A1 (en) 2018-08-16
JP2020507582A (ja) 2020-03-12
KR102549952B1 (ko) 2023-06-29
HRP20212000T1 (hr) 2022-04-01
CN110520423B (zh) 2022-08-23
BR112019016635A2 (pt) 2020-04-07
EP3580220A1 (en) 2019-12-18
CA3053484A1 (en) 2018-08-16
PT3580220T (pt) 2022-01-03
AU2018217488A1 (en) 2019-10-03
CY1124978T1 (el) 2023-01-05
RS62801B1 (sr) 2022-02-28
EA039808B1 (ru) 2022-03-16
EP3580220B1 (en) 2021-11-17
HUE057801T2 (hu) 2022-06-28
EA201991915A1 (ru) 2019-12-30
ES2902676T3 (es) 2022-03-29
LT3580220T (lt) 2021-12-27
MX2019009555A (es) 2019-10-02

Similar Documents

Publication Publication Date Title
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3209656T3 (da) Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3271349T3 (da) Benzimidazolederivater som bromodomain-inhibitorer
DK2981526T3 (da) Naphthylureaderivater til anvendelse som kinaseinhibitorer
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3728207T3 (da) Quinazolinoner som parp14-inhibitorer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3704118T3 (da) Aminoimidazopyrazin som kinasehæmmere
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer